ClinicalTrials.gg
CompletedNCT04882878Updated Dec 8, 2025

A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

A Phase 2 interventional study of Placebo and Nipocalimab in Systemic Lupus Erythematosus, sponsored by Janssen Research & Development, LLC. Completed at 86 sites in 12 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Lupus Erythematosus, Systemic by Johnson & Johnson — 1 open to participants now, 1 under way, 1 of them phase 3. Lupus Erythematosus, Systemic · Johnson & Johnson.

Started
2021
the only one that year
Phase 2
2 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Lupus Erythematosus, Systemic by Johnson & Johnson, this one is the only one that started in 2021, is one of 2 in phase 2, and was the 9th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

1 of the 10 studies in Lupus Erythematosus, Systemic by Johnson & Johnson is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Lupus Erythematosus, Systemic by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).

Read the detailed description

SLE is a complex, immune-mediated inflammatory disorder of unknown etiology that can affect almost any organ system and follows a waxing and waning disease course. In SLE, the immune system attacks the body cells and tissues and the resulting inflammation and tissue damage can harm the heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous system. Nipocalimab is a fully human aglycosylated immunoglobulin (Ig)G1 monoclonal antibody designed to selectively bind, saturate, and block the IgG binding site on the endogenous neonatal fragment crystallizable receptor (FcRn). Thus, nipocalimab, a FcRn antibody, has potential in treatment of SLE through lowering of pathogenic IgGs and immune complexes. The study will consist of a Screening Period (less than or equal to [\<=] 6 Weeks), double-blind Treatment Period (52 Weeks), and a Follow-up Period (6 Weeks). Key safety assessments will include adverse events (AEs), serious adverse events (SAEs), adverse events of special interests (AESIs), clinical laboratory tests (hematology, chemistry, urinalysis, and lipid profile) and vital signs. The total duration of the study is up to 64 weeks.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Lupus
  • SLE
  • Nipocalimab
  • Lupus SLE
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a clinical diagnosis of systemic lupus erythematosus (SLE) greater than or equal to (>=) 6 months prior to the screening visit and according to Systemic Lupus International Collaborating Clinics (SLICC)-2012 classification criteria: at least 4 criteria fulfilled, with at least 1 clinical criterion and 1 immunologic criterion
  • Has at least 1 BILAG (british isles lupus assessment group) A and/or 2 BILAG B scores observed during screening
  • Must have at least moderately active SLE, as defined as systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) score >= 6 at screening visit. Must also have SLEDAI 2K >= 4 for clinical features (that is, SLEDAI-2K score excluding headache and laboratory abnormalities) present at Week 0 prior to randomization
  • Has a CLASI (cutaneous lupus erythematosus disease area and severity index) activity score of at least 6 (excluding diffuse non-inflammatory alopecia) or at least 4 joints with pain and signs of inflammation (active joints) at screening or at Week 0, or both
  • At least 1 unequivocally positive autoantibody test including antinuclear antibodies (ANA) (>= 1:80) and/or anti-double stranded deoxyribonucleic acid (dsDNA) antibodies (level >= 75 international units/milliliter [IU/mL]) and/or anti-Smith antibodies (>120 Absorbance unit/milliliter [AU/mL]) detected during screening
  • Must be receiving 1 or more of the following protocol-permitted, systemic standard-of-care treatments prior to first administration of study intervention at a stable dose: oral , antimalarial or up to 2 immunomodulatory drugs

Exclusion criteria

Exclusion Criteria:

  • Current or history of, severe, progressive, or uncontrolled renal disease, with the exception of active lupus nephritis (LN). Have severe active LN as determined by sponsor (or designee) adjudication. Control of renal disease must be documented with at least 2 measurements of proteinuria or urine protein/creatinine ratio (UPCR) over the 6 months prior to screening
  • Has any unstable or progressive manifestation of SLE that is likely to warrant escalation in therapy beyond permitted background medications
  • Confirmed or suspected inflammatory diseases that might confound the evaluations of efficacy
  • Has a severe infection including opportunistic infections requiring parenteral anti-infectives, and/or hospitalization within 8 weeks prior to screening
  • Has received a single B-cell targeting agent within 3 months prior to first administration of study intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
228 participants (actual)

Study arms

  • Placebo comparator
    Group 1: Placebo

    Participants will receive placebo intravenously (IV) every two weeks (q2w) through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and Glucocorticoids \[GCs\]).

    Other: Placebo · Drug: Standard-of-care treatment

  • Experimental
    Group 2: Nipocalimab Dose 1

    Participants will receive nipocalimab dose 1 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).

    Drug: Nipocalimab · Drug: Standard-of-care treatment

  • Experimental
    Group 3: Nipocalimab Dose 2

    Participants will receive nipocalimab dose 2 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).

    Drug: Nipocalimab · Drug: Standard-of-care treatment

Interventions

  • OtherPlacebo

    Placebo will be administered intravenously.

  • Nipocalimab dose 1 and dose 2 will be administered intravenously.

    Also known as: JNJ-80202135, M281

  • DrugStandard-of-care treatment

    Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index (SRI)-4 Composite Response at Week 24

    SLE SRI-4 composite response is a composite of at least 4-point improvement in SLE Disease Activity Index 2000(SLEDAI-2K), no worsening in British Isles Lupus Assessment Group (BILAG), no worsening in Physician's Global Assessment of Disease Activity score (PGA) and not meeting study treatment failure criteria.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants with Baseline Active Mucocutaneous Lupus Manifestations (Cutaneous Lupus Erythematosus Disease Area and Severity Index [CLASI] Activity Score >= 6) Achieving >= 50 Percent (%) Reduction in the CLASI Activity Score at Week 24

    Percentage of participants achieving at least 50% improvement in CLASI Activity Score at Week 24 will be reported in participants with a CLASI Activity Score of 6 or greater at baseline. Cutaneous lupus disease activity and severity will be measured by the CLASI. The CLASI is an instrument to assess the disease activity and damage caused to the skin for cutaneous lupus erythematosus participants with or without systemic involvement. The CLASI consists of 2 scores; the first summarizes the activity of the disease while the second is a measure of the damage caused by the disease.

    Time frame: Week 24

  2. Percentage of Participants with Baseline Arthritis (with at Least 4 Active Joints at Baseline) Achieving >= 50% Reduction in Active Joints at Week 24

    Percentage of participants with baseline arthritis (with at least 4 active joints at baseline) achieving \>= 50% reduction in active joints at Week 24 will be reported.

    Time frame: Week 24

  3. Percentage of Participants with >= 4 Point Improvement in SLE Disease Activity Index 2000 (SLEDAI-2K) at Week 24

    Percentage of participants achieving at least 4 point improvement in SLEDAI-2K will be reported. The SLEDAI-2K is an established, validated SLE activity index. It is based on the presence of 24 features in 9 organ systems and measures disease activity in SLE participants at the time of the visit or in the previous 30 days; the index is weighted according to the feature. Features are scored by the assessing physician if present at the time of the visit or within the last 30 days, with more severe features having higher scores, and then simply added to determine the total SLEDAI-2K score, which ranges from 0 to 105, with higher scores representing increased disease activity.

    Time frame: Week 24

  4. Percentage of Participants Achieving the British Isles Lupus Assessment Group (BILAG) Composite Lupus Assessment (BICLA) Response at Week 24

    Percentage of participants achieving BICLA Response (BILAG-2004 disease activity improvement without worsening, and without worsening of SLEDAI-2K or PGA compared to baseline) at Week 24 will be reported.

    Time frame: Week 24

  5. Time to First Flare Through Week 24

    Time to first flare through Week 24, with flare defined as either 1 or more new BILAG A or 2 or more new BILAG B scores will be reported.

    Time frame: Up to Week 24

  6. Percentage of Participants Achieving SRI-4 Composite Response at Week 52

    Percentage of participants achieving SRI-4 composite response at Week 52 will be reported.

    Time frame: Week 52

  7. Percentage of Participants Receiving >= 10 milligram/day (mg/day) Prednisone or Equivalent at Baseline who Achieve Week 6-16 Glucocorticoid (GC) Taper Goal (at Week 16 to <= 7.5 mg/day Prednisone or Equivalent) and Maintain that Reduction Until Week 24

    Percentage of participants receiving \>= 10 mg/day prednisone or equivalent at baseline who achieve Week 6-16 GC taper goal (at Week 16 to \<= 7.5 mg/day prednisone or equivalent) and maintain that reduction until Week 24 will be reported.

    Time frame: Up to Week 24

  8. Percentage of Participants with Treatment-emergent Adverse Events (TEAEs) Through Week 58

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

    Time frame: Up to Week 58

  9. Percentage of Participants with Treatment-emergent Serious Adverse Events (SAEs) Through Week 58

    SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. Treatment-emergent SAEs are defined as SAEs with onset or worsening on or after date of first dose of study treatment.

    Time frame: Up to Week 58

  10. Percentage of Participants with Treatment-emergent Adverse Events of Special interests (AESIs) Through Week 58

    Percentage of participants with treatment-emergent AESIs will be reported. Treatment-emergent adverse events associated with the following situations are considered as AESIs: infections that are severe or require intravenous anti-infective or operative/invasive intervention, hypoalbuminemia with albumin less than (\<) 20 gram/liter (g/L) (\<2.0 gram/deciliter \[g/dL\]).

    Time frame: Up to Week 58

  11. Percentage of Participants with Treatment-emergent AEs leading to treatment discontinuation Through Week 58

    Percentage of participants with treatment-emergent AEs leading to discontinuation of study intervention will be reported.

    Time frame: Up to Week 58

  12. Number of Participants with Change from Baseline in Laboratory Parameters Over Time

    Number of participants with change from baseline in laboratory parameters (hematology, chemistry, urinalysis and lipid profile) over time will be reported.

    Time frame: Up to Week 58

  13. Number of Participants with Change from Baseline in Vital Signs Parameters Over Time

    Number of participants with change from baseline in vital sign parameters (temperature, pulse/heart rate, respiratory rate, and blood pressure) will be reported.

    Time frame: Up to Week 58

  14. Serum Concentration of Nipocalimab Over Time

    Serum concentrations of nipocalimab over time in participants receiving active study intervention will be reported.

    Time frame: Up to Week 58

  15. Number of Participants with Antibodies to Nipocalimab (Anti-Drug Antibodies [ADAs] and Neutralizing Antibodies [Nabs])

    Number of participants with antibodies to nipocalimab (ADAs and Nabs) in participants receiving active study intervention will be reported.

    Time frame: Up to Week 58

07

Study locations

86 sites
  • Valerius Medical Group & Research Center
    Los Alamitos, California 90720, United States
  • Desert Medical Advances
    Rancho Mirage, California 92270, United States
  • Wolverine Clinical Trials
    Santa Ana, California 92705, United States
  • Millennium Clinical Trials LLC
    Westlake Village, California 91361, United States
  • Bay Area Arthritis and Osteoporosis
    Brandon, Florida 33511, United States
  • GNP Research
    Cooper City, Florida 33024, United States
  • South Coast Research Center
    Miami, Florida 33136, United States
  • Advanced Clinical Research of Orlando
    Ocoee, Florida 34761, United States
  • Omega Research Consultants
    Orlando, Florida 32808, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • North Georgia Rheumatology, PC
    Lawrenceville, Georgia 30046, United States
  • Atlanta Research Center for Rheumatology
    Marietta, Georgia 30060, United States
  • West County Rheumatology
    St Louis, Missouri 63131, United States
  • DJL Clinical Research, PLLC
    Charlotte, North Carolina 28210, United States
  • Paramount Medical Research & Consulting
    Middleburg Heights, Ohio 44130, United States
  • Dr. Ramesh Gupta
    Memphis, Tennessee 38119, United States
  • Arthritis and Rheumatology Research Institute
    Allen, Texas 75013, United States
  • Precision Comprehensive Clinical Research Solutions
    Colleyville, Texas 76034, United States
  • Southwest Rheumatology Research LLC
    Mesquite, Texas 75150, United States
  • Epic Medical Research
    Red Oak, Texas 75154, United States
  • Rheumatology and Pulmonary Clinic
    Beckley, West Virginia 25801, United States
  • Centro Médico Reumatológico (OMI)
    Buenos Aires, C1015ABO, Argentina
  • Centro Privado de Medicina Familiar
    Buenos Aires, C1417EYG, Argentina
  • ARCIS Salud SRL Aprillus asistencia e investigacion
    CABA, C1406AGA, Argentina
  • Clinica Adventista Belgrano
    Ciudad de Buenos Aires, C1430EGF, Argentina
  • Hospital Italiano La Plata
    La Plata, B1900, Argentina
  • Centro de Investigaciones Medicas Mar Del Plata
    Mar del Plata, B7600, Argentina
  • Instituto de Reumatologia - Ir Medical Center S.A.
    Mendoza, 5000, Argentina
  • Centro de Investigaciones Medicas Tucuman
    San Miguel de Tucumán, T4000AXL, Argentina
  • Multiprofile Hospital for Active Treatment Plovdiv
    Plovdiv, 4000, Bulgaria
  • Diagnostic-Consultative Center (DCC) Aleksandrovska
    Sofia, 1431, Bulgaria
  • UMHAT St. Ivan Rilski
    Sofia, 1612, Bulgaria
  • Clinica de la Costa SAS
    Barranquilla, 080001, Colombia
  • Centro de Investigacion Medico Asistencial SAS - CIMEDICAL SAS
    Barranquilla, 080020, Colombia
  • Centro de Investigación en Reumatología y especialidades médicas S.A.S. - CIREEM S.A.S.
    Bogotá, 110221, Colombia
  • Servimed S A S
    Bucaramanga, Colombia
  • IPS Preventive Care SAS
    Chía, Colombia
  • Praxis Dr. med. Beate Schwarz - Germany
    Langenau, 89129, Germany
  • Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
  • Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz
    Budapest, 1023, Hungary
  • Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz
    Gyula, 5700, Hungary
  • Belvarosi Egeszseghaz Kft. (Leda-Platan Maganklinika es Sebeszeti Kozpont)
    Zalaegerszeg, H-8900, Hungary
  • National Hospital Organization Chiba East Hospital
    Chiba, 260-8712, Japan
  • National Hospital Organization Kyushu Medical Center
    Fukuoka, 810 8563, Japan
  • National Center for Global Health and Medicine Kohnodai hospital
    Ichikawa, 272 8516, Japan
  • St Marianna University Hospital
    Kanagawa, 216 8511, Japan
  • National Hospital Organization Osaka Minami Medical Center
    Kawachi-Nagano, 586 8521, Japan
  • National Hospital Organization Nagoya Medical Center
    Nagoya, 460-0001, Japan
  • Osaka Metropolitan University Hospital
    Osaka, 545 8586, Japan
  • Tohoku University Hospital
    Sendai, 980 8574, Japan
  • Osaka Medical and Pharmaceutical University Hospital
    Takatsuki, 569-8686, Japan
  • St. Luke's International Hospital
    Tokyo, 104 8560, Japan
  • Fujita Health University Hospital
    Toyoake, 470-1192, Japan
  • University of Tsukuba Hospital
    Tsukuba, 305 8576, Japan
  • Szpital Uniwersytecki Nr 2 w Bydgoszczy
    Bydgoszcz, 85 168, Poland
  • Nzoz Bif Med
    Bytom, 41 902, Poland
  • Malopolskie Badania Kliniczne Sp z o o
    Krakow, 30-002, Poland
  • Centrum Medyczne Plejady
    Krakow, 30363, Poland
  • NZOZ Lecznica MAK MED S C
    Nadarzyn, 05-830, Poland
  • Twoja Przychodnia Poznanskie Centrum Medyczne
    Poznan, 60-324, Poland
  • AI Centrum Medyczne
    Poznan, 61 113, Poland
  • Prywatna Praktyka Lekarska Prof Um Dr Hab Med Pawel Hrycaj
    Poznan, 61 397, Poland
  • Uniwersytecki Szpital Kliniczny w Rzeszowie
    Rzeszów, 35-055, Poland
  • MICS Centrum Medyczne Warszawa
    Warsaw, 00-874, Poland
  • Panorama Medical Centre
    Cape Town, 7500, South Africa
  • Excellentis Clinical trial Consultants
    George, 6529, South Africa
  • Winelands Rheumatology Centre
    Stellenbosch, 7600, South Africa
  • Hosp Univ Vall D Hebron
    Barcelona, 08035, Spain
  • Hosp. Univ. Ramon Y Cajal
    Madrid, 28034, Spain
  • Hosp. de Navarra
    Pamplona, 31008, Spain
  • Corporacio Sanitari Parc Tauli
    Sabadell, 08208, Spain
  • Hospital Clinico Universitario Lozano Blesa
    Zaragoza, 50009, Spain
  • Kaohsiung Veterans General Hospital
    Kaohsiung City, 81362, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung City, 88301, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • Taipei Medical University
    Taipei, 11031, Taiwan
  • Municipal Non-Profit Enterprise 'Chernihiv Regional Hospital' of Chernihiv Regional Council
    Chernihiv, 14029, Ukraine
  • Municipal Non-Profit Enterprise of Kharkiv Regional Council 'Regional Clinical Hospital'
    Kharkiv, 61204, Ukraine
  • Medical Center 'Ok Clinic' of International Institute of Clinical Research LLC
    Kyiv, 02091, Ukraine
  • Medbud-Clinic LLC
    Kyiv, 03037, Ukraine
  • Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'
    Kyiv, 03049, Ukraine
  • Medical Center 'Consylium Medical'
    Kyiv, 04050, Ukraine
  • Municipal Non-profit Enterprise 'Odesa Regional Clinical Hospital' Odesa Regional Council
    Odesa, 65025, Ukraine
  • ME Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of Poltava Regional Consuil
    Poltava, 36011, Ukraine
  • MNPE 'Vinnytsia Regional Clinical Hospital named after M.I. Pyrogov of Vinnytsia Regional Council'
    Vinnytsia, 21018, Ukraine
  • Medical Center LLC 'Modern Clinic'
    Zaporizhzhya, 69600, Ukraine
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Apr 2024, 32 months.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 32 months is close to that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2021
First posted
May 12, 2021
StartActual
Aug 20, 2021
Primary completionActual
Apr 30, 2024
CompletionActual
Dec 26, 2024
Results delay requested
Mar 19, 2025
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04882878
Responsible party
Sponsor
First posted
May 12, 2021
Start date
Aug 20, 2021
Primary completion
Apr 30, 2024
Completion
Dec 26, 2024
Last update
Dec 8, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nipocalimab

Start the discussion